Karyopharm Therapeutics (KPTI) Presents Clinical Data On Selinexor (KPT-330) In Colorectal Cancer From Ongoing Phase 1 Study And Preclinical Data On Novel PAK4 Inhibitors At American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium
1/22/2014 8:49:15 AM
NATICK, Mass., Jan. 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced data from two poster presentations at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal (GI) Cancers Symposium that took place January 16-18 in San Francisco, California. The data presented included an update (as of December 16, 2013) from the ongoing Phase 1 study of oral Selinexor in solid tumors that show preliminary evidence of antitumor activity in metastatic colorectal cancer (CRC) patients. Additionally, data were presented on novel, oral p21-activated kinase 4 (PAK4) inhibitors that show anti-proliferative activity and tolerability in a preclinical pancreatic cancer model.
Help employers find you! Check out all the jobs and post your resume.
comments powered by